<DOC>
	<DOCNO>NCT02412917</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , parallel-group , active control comparative study safety efficacy 2 dose regimen FV-100 versus valacyclovir administer 7 day subject uncomplicated AHZ ( acute herpes zoster ) .</brief_summary>
	<brief_title>A Comparative Study FV-100 vs. Valacyclovir Prevention Post-Herpetic Neuralgia</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , parallel-group , active control comparative study safety efficacy 2 dose regimen FV-100 versus valacyclovir administer 7 day subject uncomplicated AHZ ( acute herpes zoster ) . Subjects diagnose uncomplicated AHZ within 72 hour lesion appearance bad pain 4 great day 1 , randomize ( 1:1:1 ) one three treatment group begin study treatment Day 1 visit ( within 72 hour AHZ lesion appearance ) either : 1 . FV-100 400mg QD , 2 . FV-100 400mg BID ( total daily dose 800mg ) , 3 . Valacyclovir 1000mg 3 time day total daily dose 3000mg . Subjects monitor adverse event day 21 . Efficacy assessment lesion status AHZ pain capture til day 120 .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Receive clinical diagnosis uncomplicated AHZ evidence unilateral dermatomal rash Have zosterrelated pain Are able randomized receive first dose within approximately 120 hour appearance rash Have multidermal disseminate AHZ Have facial , ophthalmologic oral manifestation Have receive Zostavax</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>